MDAT
Sign in to saveAlso known as 6,7-methylenedioxy-2-aminotetralin
MDAT, also known as 6,7-methylenedioxy-2-aminotetralin, is a drug of the 2-aminotetralin family developed in the 1990s by a team at Purdue University led by David E. Nichols. It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity. Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.
~1 min read
Encyclopedic overview
3 sectionsContents
- See also
- References
- External links
MDAT, also known as 6,7-methylenedioxy-2-aminotetralin, is a drug of the 2-aminotetralin family developed in the 1990s by a team at Purdue University led by David E. Nichols. It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity. Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.
==See also== Substituted 2-aminotetralin Substituted methylenedioxyphenethylamine Cyclized phenethylamine
Excerpted from Wikipedia’s “MDAT” article, available under the CC BY-SA 4.0 licence.